Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Matternet, Inc.NONE · Entity 26314 | Director | May 22, 2026 | May 27, 2026 |
| RenovoRx, Inc.RNXT · Entity 6797 | Director | October 01, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Matternet, Inc.
Report date May 22, 2026 · Filed May 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 52,003 |
Reported balance
After 2026-05-22 transaction · row 1
1 source rowRow 1 · 2026-05-22 · Grant · Acquired 52,003 · Balance 52,003 F1: Received in connection with the Issuer's merger (the "Merger") with Matternet, Inc. ("Legacy Matternet") in accordance with the terms of the Agreement and Plan of Merger and Reorganization dated as of May 22, 2026, by and among the Issuer (f/k/a Los Altos Ventures Corp.), Matternet Acquisition Co. and Legacy Matternet (the "Merger Agreement"), in exchange for shares of Legacy Matternet common stock. Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of Legacy Matternet common stock was converted into the right to receive 2.0801 shares of the Issuer's common stock, rounded to the nearest whole share (the "Conversion Ratio"). |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Expires 2028-10-30 | Direct | 266,488 |
Reported balance
After 2026-05-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-22 · Grant · Acquired 266,488 · Balance 266,488 F2: Each vested and unvested option to purchase shares of common stock of Legacy Matternet outstanding immediately prior to the effective time of the Merger was assumed by the Issuer and converted into an option to purchase shares of common stock equal to the product of (a) the number of shares of common stock subject to such option immediately prior to the effective time of the Merger and (b) the Conversion Ratio, at an exercise price per share equal to (i) the exercise price per share of such option immediately prior to the effective time of the Merger divided by (ii) the Conversion Ratio. F3: The shares subject to the option shall become vested and exercisable in 48 equal monthly installments from the vesting commencement date. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Expires 2033-10-12 | Direct | 181,898 |
Reported balance
After 2026-05-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-22 · Grant · Acquired 181,898 · Balance 181,898 F2: Each vested and unvested option to purchase shares of common stock of Legacy Matternet outstanding immediately prior to the effective time of the Merger was assumed by the Issuer and converted into an option to purchase shares of common stock equal to the product of (a) the number of shares of common stock subject to such option immediately prior to the effective time of the Merger and (b) the Conversion Ratio, at an exercise price per share equal to (i) the exercise price per share of such option immediately prior to the effective time of the Merger divided by (ii) the Conversion Ratio. F4: The shares subject to the option shall become vested and exercisable in 24 equal monthly installments from the vesting commencement date. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Expires 2034-12-19 | Direct | 41,602 |
Reported balance
After 2026-05-22 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-22 · Grant · Acquired 41,602 · Balance 41,602 F2: Each vested and unvested option to purchase shares of common stock of Legacy Matternet outstanding immediately prior to the effective time of the Merger was assumed by the Issuer and converted into an option to purchase shares of common stock equal to the product of (a) the number of shares of common stock subject to such option immediately prior to the effective time of the Merger and (b) the Conversion Ratio, at an exercise price per share equal to (i) the exercise price per share of such option immediately prior to the effective time of the Merger divided by (ii) the Conversion Ratio. F3: The shares subject to the option shall become vested and exercisable in 48 equal monthly installments from the vesting commencement date. |
Filing footnotes · ownership attribution and instrument terms
F1: Received in connection with the Issuer's merger (the "Merger") with Matternet, Inc. ("Legacy Matternet") in accordance with the terms of the Agreement and Plan of Merger and Reorganization dated as of May 22, 2026, by and among the Issuer (f/k/a Los Altos Ventures Corp.), Matternet Acquisition Co. and Legacy Matternet (the "Merger Agreement"), in exchange for shares of Legacy Matternet common stock. Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of Legacy Matternet common stock was converted into the right to receive 2.0801 shares of the Issuer's common stock, rounded to the nearest whole share (the "Conversion Ratio").
F2: Each vested and unvested option to purchase shares of common stock of Legacy Matternet outstanding immediately prior to the effective time of the Merger was assumed by the Issuer and converted into an option to purchase shares of common stock equal to the product of (a) the number of shares of common stock subject to such option immediately prior to the effective time of the Merger and (b) the Conversion Ratio, at an exercise price per share equal to (i) the exercise price per share of such option immediately prior to the effective time of the Merger divided by (ii) the Conversion Ratio.
F3: The shares subject to the option shall become vested and exercisable in 48 equal monthly installments from the vesting commencement date.
F4: The shares subject to the option shall become vested and exercisable in 24 equal monthly installments from the vesting commencement date.
RenovoRx, Inc.
Report date October 01, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.55 · Expires 2036-10-01 | Direct | 55,924 |
Reported balance
After 2026-10-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-10-01 · Grant · Acquired 55,924 · Balance 55,924 F1: The shares subject to the option vest in 12 equal monthly installments beginning on November 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest in 12 equal monthly installments beginning on November 1, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 3, 2026 01:00 UTC | RenovoRx, Inc. RNXT · Entity 6797 | GrantStock Options (right to buy) · Derivative | 55,924 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0001493152-26-045577 · ownership.xml · derivative · entry 1 Marton Laurence · CIK 0001862192 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,924 Underlying: Common Stock · 55,924 shares Expires 2036-10-01 F1 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments beginning on November 1, 2026. Read SEC document |
| May 22, 2026 Filed May 27, 2026 23:52 UTC | Matternet, Inc. NONE · Entity 26314 | GrantDirector Stock Option (right to buy) · Derivative | 41,602 | $0.00 | $0.00 |
DisclosureSEC source: 0001862192-26-000003 · form4-05272026_110505.xml · derivative · entry 4 Marton Laurence · CIK 0001862192 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,602 Underlying: Common Stock · 41,602 shares Expires 2034-12-19 F2 · derivative.exercise_price: Each vested and unvested option to purchase shares of common stock of Legacy Matternet outstanding immediately prior to the effective time of the Merger was assumed by the Issuer and converted into an option to purchase shares of common stock equal to the product of (a) the number of shares of common stock subject to such option immediately prior to the effective time of the Merger and (b) the Conversion Ratio, at an exercise price per share equal to (i) the exercise price per share of such option immediately prior to the effective time of the Merger divided by (ii) the Conversion Ratio. F3 · derivative.exercise_date: The shares subject to the option shall become vested and exercisable in 48 equal monthly installments from the vesting commencement date. Read SEC document |
| May 22, 2026 Filed May 27, 2026 23:52 UTC | Matternet, Inc. NONE · Entity 26314 | GrantDirector Stock Option (right to buy) · Derivative | 181,898 | $0.00 | $0.00 |
DisclosureSEC source: 0001862192-26-000003 · form4-05272026_110505.xml · derivative · entry 3 Marton Laurence · CIK 0001862192 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 181,898 Underlying: Common Stock · 181,898 shares Expires 2033-10-12 F2 · derivative.exercise_price: Each vested and unvested option to purchase shares of common stock of Legacy Matternet outstanding immediately prior to the effective time of the Merger was assumed by the Issuer and converted into an option to purchase shares of common stock equal to the product of (a) the number of shares of common stock subject to such option immediately prior to the effective time of the Merger and (b) the Conversion Ratio, at an exercise price per share equal to (i) the exercise price per share of such option immediately prior to the effective time of the Merger divided by (ii) the Conversion Ratio. F4 · derivative.exercise_date: The shares subject to the option shall become vested and exercisable in 24 equal monthly installments from the vesting commencement date. Read SEC document |
| May 22, 2026 Filed May 27, 2026 23:52 UTC | Matternet, Inc. NONE · Entity 26314 | GrantDirector Stock Option (right to buy) · Derivative | 266,488 | $0.00 | $0.00 |
DisclosureSEC source: 0001862192-26-000003 · form4-05272026_110505.xml · derivative · entry 2 Marton Laurence · CIK 0001862192 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 266,488 Underlying: Common Stock · 266,488 shares Expires 2028-10-30 F2 · derivative.exercise_price: Each vested and unvested option to purchase shares of common stock of Legacy Matternet outstanding immediately prior to the effective time of the Merger was assumed by the Issuer and converted into an option to purchase shares of common stock equal to the product of (a) the number of shares of common stock subject to such option immediately prior to the effective time of the Merger and (b) the Conversion Ratio, at an exercise price per share equal to (i) the exercise price per share of such option immediately prior to the effective time of the Merger divided by (ii) the Conversion Ratio. F3 · derivative.exercise_date: The shares subject to the option shall become vested and exercisable in 48 equal monthly installments from the vesting commencement date. Read SEC document |
| May 22, 2026 Filed May 27, 2026 23:52 UTC | Matternet, Inc. NONE · Entity 26314 | GrantCommon Stock | 52,003 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001862192-26-000003 · form4-05272026_110505.xml · nonDerivative · entry 1 Marton Laurence · CIK 0001862192 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,003 F1 · price: Received in connection with the Issuer's merger (the "Merger") with Matternet, Inc. ("Legacy Matternet") in accordance with the terms of the Agreement and Plan of Merger and Reorganization dated as of May 22, 2026, by and among the Issuer (f/k/a Los Altos Ventures Corp.), Matternet Acquisition Co. and Legacy Matternet (the "Merger Agreement"), in exchange for shares of Legacy Matternet common stock. Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of Legacy Matternet common stock was converted into the right to receive 2.0801 shares of the Issuer's common stock, rounded to the nearest whole share (the "Conversion Ratio"). Read SEC document |
| March 20, 2026 Filed Mar 25, 2026 01:16 UTC | RenovoRx, Inc. RNXT · Entity 6797 | PurchaseWarrants · Derivative | 4,860 | Not disclosed Strike: $1.93 | Not disclosed |
DisclosureSEC source: 0001493152-26-012483 · ownership.xml · derivative · entry 2 Marton Laurence · CIK 0001862192 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Laurence Marton Rollover IRA Disclosed balance after: 4,860 Underlying: Common Stock · 4,860 shares Expires not disclosed F1 · price: The securities were purchased in a private placement on March 20, 2026 for an aggregate of $10,000. F2 · derivative.exercise_date: The warrants are exercisable immediately upon issuance and expire on the earlier of (i) March 30, 2029 or (ii) 30 days following the date the Issuer reports at least $1.5 million in product sales revenue (excluding licensing fees, upfront milestones and grants, but including royalty revenue from product sales) for any calendar quarter in a quarterly or annual report. F2 · derivative.expiration_date: The warrants are exercisable immediately upon issuance and expire on the earlier of (i) March 30, 2029 or (ii) 30 days following the date the Issuer reports at least $1.5 million in product sales revenue (excluding licensing fees, upfront milestones and grants, but including royalty revenue from product sales) for any calendar quarter in a quarterly or annual report. Read SEC document |
| March 20, 2026 Filed Mar 25, 2026 01:16 UTC | RenovoRx, Inc. RNXT · Entity 6797 | PurchaseCommon Stock | 9,720 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-26-012483 · ownership.xml · nonDerivative · entry 1 Marton Laurence · CIK 0001862192 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Laurence Marton Rollover IRA Disclosed balance after: 9,720 F1 · price: The securities were purchased in a private placement on March 20, 2026 for an aggregate of $10,000. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 13:19 UTC | RenovoRx, Inc. RNXT · Entity 6797 | GrantStock Options (right to buy) · Derivative | 47,640 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001493152-25-016789 · ownership.xml · derivative · entry 1 Marton Laurence · CIK 0001862192 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,640 Underlying: Common Stock · 47,640 shares Expires 2035-10-01 F1 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments beginning on November 1, 2025. Read SEC document |
| May 02, 2025 Filed May 6, 2025 20:10 UTC | RenovoRx, Inc. RNXT · Entity 6797 | Exercise / conversionStock Option (right to buy) · Derivative | 20,480 | $0.00 Strike: $0.15 | $0.00 |
DisclosureSEC source: 0001641172-25-008842 · ownership.xml · derivative · entry 2 Marton Laurence · CIK 0001862192 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,480 shares Expires 2025-10-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the reporting person's cash exercise of an outstanding stock option into shares of common stock, with no sale of such shares of common stock. F2 · derivative.exercise_date: Shares subject to the option are fully vested and immediately exercisable. Read SEC document |
| May 02, 2025 Filed May 6, 2025 20:10 UTC | RenovoRx, Inc. RNXT · Entity 6797 | Exercise / conversionCommon Stock | 20,480 | $0.15 | $3,072.00 |
DisclosureSEC source: 0001641172-25-008842 · ownership.xml · nonDerivative · entry 1 Marton Laurence · CIK 0001862192 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,164 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the reporting person's cash exercise of an outstanding stock option into shares of common stock, with no sale of such shares of common stock. Read SEC document |
| April 08, 2025 Filed Apr 10, 2025 01:30 UTC | RenovoRx, Inc. RNXT · Entity 6797 | PurchaseCommon Stock | 12,050 | $0.85 | $10,218.40 |
DisclosureSEC source: 0001641172-25-003496 · ownership.xml · nonDerivative · entry 1 Marton Laurence · CIK 0001862192 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,684 F1 · shares: Reflects an open market purchase of the Issuer's securities. Read SEC document |
| October 01, 2024 Filed Oct 2, 2024 20:30 UTC | RenovoRx, Inc. RNXT · Entity 6797 | GrantStock Options (right to buy) · Derivative | 25,099 | $0.00 Strike: $1.02 | $0.00 |
DisclosureSEC source: 0001493152-24-039217 · ownership.xml · derivative · entry 1 Marton Laurence · CIK 0001862192 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,099 Underlying: Common Stock · 25,099 shares Expires 2034-10-01 F1 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments beginning on November 1, 2024. Read SEC document |
| January 26, 2024 Filed Jan 30, 2024 23:32 UTC | RenovoRx, Inc. RNXT · Entity 6797 | PurchaseWarrants · Derivative | 8,196 | Not disclosed Strike: $1.22 | Not disclosed |
DisclosureSEC source: 0001493152-24-004366 · ownership.xml · derivative · entry 2 Marton Laurence · CIK 0001862192 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,196 Underlying: Common Stock · 8,196 shares Expires not disclosed F1 · price: Reporting Person purchased 8,196 shares of common stock and warrants to purchase 8,196 shares of common stock for a purchase price of $1.22 per share of common stock and associated warrant exercisable for one share of common stock in a private placement offering by the company made pursuant to Rule 506(c) of the Securities Act of 1933, as amended. The warrants are exercisable immediately, at an exercise price of $1.22 per share, subject to certain adjustments, and expire on January 30, 2029. F1 · derivative.exercise_date: Reporting Person purchased 8,196 shares of common stock and warrants to purchase 8,196 shares of common stock for a purchase price of $1.22 per share of common stock and associated warrant exercisable for one share of common stock in a private placement offering by the company made pursuant to Rule 506(c) of the Securities Act of 1933, as amended. The warrants are exercisable immediately, at an exercise price of $1.22 per share, subject to certain adjustments, and expire on January 30, 2029. F1 · derivative.expiration_date: Reporting Person purchased 8,196 shares of common stock and warrants to purchase 8,196 shares of common stock for a purchase price of $1.22 per share of common stock and associated warrant exercisable for one share of common stock in a private placement offering by the company made pursuant to Rule 506(c) of the Securities Act of 1933, as amended. The warrants are exercisable immediately, at an exercise price of $1.22 per share, subject to certain adjustments, and expire on January 30, 2029. Read SEC document |
| January 26, 2024 Filed Jan 30, 2024 23:32 UTC | RenovoRx, Inc. RNXT · Entity 6797 | PurchaseCommon Stock | 8,196 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-24-004366 · ownership.xml · nonDerivative · entry 1 Marton Laurence · CIK 0001862192 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,634 F1 · price: Reporting Person purchased 8,196 shares of common stock and warrants to purchase 8,196 shares of common stock for a purchase price of $1.22 per share of common stock and associated warrant exercisable for one share of common stock in a private placement offering by the company made pursuant to Rule 506(c) of the Securities Act of 1933, as amended. The warrants are exercisable immediately, at an exercise price of $1.22 per share, subject to certain adjustments, and expire on January 30, 2029. Read SEC document |
| October 01, 2023 Filed Oct 2, 2023 20:15 UTC | RenovoRx, Inc. RNXT · Entity 6797 | GrantStock Options (right to buy) · Derivative | 25,099 | $0.00 Strike: $1.33 | $0.00 |
DisclosureSEC source: 0001493152-23-035035 · ownership.xml · derivative · entry 1 Marton Laurence · CIK 0001862192 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,099 Underlying: Common Stock · 25,099 shares Expires 2033-10-01 F1 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments beginning on November 1, 2023 Read SEC document |
| November 03, 2022 Filed Nov 4, 2022 20:48 UTC | RenovoRx, Inc. RNXT · Entity 6797 | Exercise / conversionStock Option (right to buy) · Derivative | 25,438 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0001209191-22-055815 · doc4.xml · derivative · entry 2 Marton Laurence · CIK 0001862192 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,438 shares Expires 2023-04-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Shares subject to the option are fully vested and immediately exercisable. Read SEC document |
| November 03, 2022 Filed Nov 4, 2022 20:48 UTC | RenovoRx, Inc. RNXT · Entity 6797 | Exercise / conversionCommon Stock | 25,438 | $1.70 | $43,244.60 |
DisclosureSEC source: 0001209191-22-055815 · doc4.xml · nonDerivative · entry 1 Marton Laurence · CIK 0001862192 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,438 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2022 Filed Oct 4, 2022 20:36 UTC | RenovoRx, Inc. RNXT · Entity 6797 | GrantStock Option (right to buy) · Derivative | 25,099 | $0.00 Strike: $2.02 | $0.00 |
DisclosureSEC source: 0001209191-22-052262 · doc4.xml · derivative · entry 1 Marton Laurence · CIK 0001862192 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,099 Underlying: Common Stock · 25,099 shares Expires 2032-10-01 F1 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments beginning on November 1, 2022. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 20:49 UTC | RenovoRx, Inc. RNXT · Entity 6797 | GrantStock Option (right to buy) · Derivative | 4,582 | $0.00 Strike: $3.17 | $0.00 |
DisclosureSEC source: 0001209191-22-018494 · doc4.xml · derivative · entry 1 Marton Laurence · CIK 0001862192 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,582 Underlying: Common Stock · 4,582 shares Expires 2032-03-10 F1 · derivative.exercise_date: The shares subject to the option vest in twelve equal monthly installments beginning on November 1, 2021. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 20:42 UTC | RenovoRx, Inc. RNXT · Entity 6797 | GrantStock Option (right to buy) · Derivative | 11,154 | $0.00 Strike: $5.91 | $0.00 |
DisclosureSEC source: 0001209191-21-059466 · doc4.xml · derivative · entry 1 Marton Laurence · CIK 0001862192 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,154 Underlying: Common Stock · 11,154 shares Expires 2031-10-01 F1 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments beginning on November 1, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.